
This study evaluates the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes that vary across the full range of ejection fraction (EF) in HF patients. Of 587 patients randomized (293 dapagliflozin, 294 placebo), EF was ≤40. Dapagliflozin improved KCCQ-CSS at 12 weeks (placebo-adjusted difference of 5.0 points). The benefits of dapagliflozin on KCCQ-CSS were also consistent when analyzing EF continuously. In responder analyses, fewer dapagliflozin-treated patients had deterioration, and more had small, moderate, and considerable KCCQ-CSS improvements versus placebo; these results were also consistent regardless of EF. In patients with HF, dapagliflozin significantly improves symptoms and physical limitations after 12 weeks of treatment, with consistent and clinically meaningful benefits across the full range of EF.
Like
Save
Share